Key result
Rosuvastatin attenuates ventricular hypertrophy, remodeling, and dysfunction in a rat model of heart failure.
Why the study?
The study was conducted to examine the protective impact of rosuvastatin on isoproterenol-induced chronic heart failure and investigate plausible related mechanisms.
Does rosuvastatin prevent cardiac dysfunction and hypertrophy in an isoproterenol-induced heart failure model in rodents?
Does rosuvastatin prevent cardiac dysfunction and hypertrophy in an isoproterenol-induced heart failure model in rodents?
Rosuvastatin demonstrated cardioprotective effects against isoproterenol-induced heart failure in a rodent model, suggesting potential pleiotropic benefits in heart failure.
Answers are grounded in this paper and cite their sources.
Should not change HF practice; hypothesis-generating for statin pleiotropy in rodent models.
Cardiovascular disease is the primary cause of mortality and morbidity, and its terminal phase is chronic heart failure. The present study aimed to examine the protective impact of rosuvastatin on isoproterenol-induced chronic heart failure and investigate plausible related mechanisms. Rosuvastatin, a drug with multiple pleiotropic properties, has been examined for its cardioprotective effects in heart failure induced by isoproterenol. Male Sprague Dawley rats were given isoproterenol 5 mg/kg once a day for 7 days to establish heart failure by subcutaneous injection. Simultaneously, rosuvastatin (10 mg/kg) was orally administrated from day 1 to day 14. Protective effects were evaluated by heart grading and gross morphology, hemodynamic parameter, cardiac troponin I, heart mitochondrial enzyme and lysosomal hydrolases and pro inflammatory cytokines levels were analyzed. Rosuvastatin (10 mg/kg) significantly attenuated isoproterenol-induced hypertrophy, remodeling and dysfunction of the ventricle, reduced the heart mitochondrial enzyme and lysosomal hydrolases and normalized the increased hemodynamic and pro inflammatory cytokines levels. The study highlights the preventive effects of, rosuvastatin, against heart failure. The results of the research indicate that rosuvastatin has cardioprotective effects on the experimental model, which were supported by several characteristics. However, further research is required to identify the precise molecular mechanisms and signalling pathways of rosuvastatin's impact on heart failure.
No takes yet. Share an insight, caveat, or question.
Wasim et al. (2023) studied Isoproterenol-induced chronic heart failure. Rosuvastatin vs. Isoproterenol alone was evaluated on Cardiac hypertrophy, remodeling, dysfunction, and biomarker levels. Rosuvastatin attenuated isoproterenol-induced ventricular hypertrophy, remodeling, and dysfunction in a rat model of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: